Genprex Receives U.S. FDA Fast Track Designation For REQORSA Immunogene Therapy In Combination With Tecentriq For Treatment Of Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
Genprex has received Fast Track Designation from the U.S. FDA for its REQORSA immunogene therapy. The therapy, used in combination with Tecentriq, is for the treatment of small cell lung cancer.
June 28, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genprex's stock may see positive movement due to the FDA's Fast Track Designation for its REQORSA immunogene therapy.
Fast Track Designation by the FDA is a significant regulatory milestone that can expedite the development and review of a drug. This news could be seen as a positive development by investors, potentially leading to an increase in Genprex's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100